MERCK
20.12.2021 14:02:06 CET | Business Wire | Press release
Merck, a leading science and technology company, today announced a strategically focused expansion of its neurology pipeline with the acquisition of the rights to develop cladribine for the treatment of generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Merck entered into an agreement to secure the global rights by acquiring Chord Therapeutics, a Swiss-based biotech company focused on rare neuroinflammatory diseases.
“Cladribine has a unique mechanism of action which is relevant in antibody-mediated disease such as NMOSD and gMG. In exploratory studies, cladribine demonstrated promising results in these diseases. These data have prompted us to initiate further development with cladribine in gMG and NMOSD to potentially bring a new therapeutic option to patients and expand our portfolio in this area,” said Danny Bar-Zohar, MD, Head of Global Development for the biopharma business of Merck.
Cladribine is a well characterized molecule that has been extensively studied across MS and oncologic disorders and has shown promising results in exploratory studies in gMG and NMOSD. Merck plans to leverage its existing capabilities to further develop an oral cladribine product tailored specifically for these indications. The transaction is expected to be closed in early 2022 after satisfactory completion of customary closing conditions.
Generalized myasthenia gravis is a disease in which patients experience weakness in ocular, limb, and respiratory muscles and that has a significant impact on Quality of Life. It is estimated that 700,000 people around the world are living with gMG. NMOSD, also known as Devic´s disease, is an autoimmune disease, often misdiagnosed as MS due to similar symptoms. NMOSD is estimated to impact 200,000 people around the world.
About Chord Therapeutics
Chord Therapeutics is a Swiss-based clinical stage pharmaceutical company developing drugs for patients with rare, life-threatening and severely disabling diseases. Chord is advancing its lead drug candidate, CRD1 (cladribine), for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and generalized myasthenia gravis (gMG). Chord Therapeutics was founded in 2014 and launched in October 2020 with Series A funding by its sole investor, Omega Funds, a leading international venture capital firm focused on delivering impactful medicines to patients.
Merck in Neurology and Immunology
Merck has a long-standing legacy in neurology and immunology, with significant R&D and commercial experience in multiple sclerosis (MS). The company`s current MS portfolio includes two products for the treatment of relapsing MS – Rebif® (interferon beta-1a) and MAVENCLAD® (cladribine tablets). Merck aims to improve the lives of patients by addressing areas of unmet medical needs. In addition to Merck`s commitment to MS, the company also has a pipeline focusing on discovering new therapies that have the potential in other neuroinflammatory and immune-mediated diseases, including systemic lupus erythematosus (SLE).
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.
About Merck
Merck, a leading science and technology company, operates across healthcare, life science and electronics. Around 58,000 employees work to make a positive difference to millions of people’s lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2020, Merck generated sales of € 17.5 billion in 66 countries.
Scientific exploration and responsible entrepreneurship have been key to Merck’s technological and scientific advances. This is how Merck has thrived since its founding in 1668. The founding family remains the majority owner of the publicly listed company. Merck holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the business sectors of Merck operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Electronics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211220005062/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kao’s Laurier Launches New Brand Communication Initiative across Asia: Strengthening Global Integration as a Core Brand in Kao’s Asian Business4.3.2026 03:10:00 CET | Press release
Starting on International Women’s Day, March 8, Kao Corporation (TOKYO:4452) will launch new brand communication campaign in nine Asian countries and regions for its feminine sanitary product brand, Laurier, which is the core of its Asian business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303996141/en/ Laurier Campaign Key Visual Laurier aims to help create more supportive and understanding environments around menstruation, so that women can feel more at ease, both physically and emotionally, under the key message “Comfort, Made Together,” which will be implemented simultaneously across Asia. Kao aims to further develop Laurier as a global brand. Laurier, one of the core brands supporting Kao’s consumer care business in Asia, has been promoting globally integrated operations since 2023. Across all nine Asian countries and regions including Japan, Laurier has been working to unify product specifications and consolida
FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World ...3.3.2026 23:06:00 CET | Press release
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303105064/en/ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ FIFA World Cup 2026™ Mascots and Representatives from the New York New Jersey Host Committee, U.S. Soccer Federation, Mexico Football Federation and Canada Soccer Light the Empire State Building to Celebrate 100 Days to Go Until the FIFA World Cup 2026™ On Tuesday, March 3, the Empire State Building will rotate in the colors of the flags of the three host countries – the United States, Canada, and Mexico – to mark 100 days to go until the FIFA World Cup 2026™. Earlier today, the Empire State Building hosted a special tower lighting ceremony with Alex Lasry, CEO of the FIFA World Cup 26™ New York New Jersey Host C
SES Publishes 2025 Annual Report3.3.2026 21:41:00 CET | Press release
SES S.A. has today published its 2025 Annual Report, following the announcement of the company’s full year financial results for the 12 months ended 31 December 2025. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry leadership—backed by a track record of bringing innovation “firsts” to market. As a trusted partner to customers and the global space ecosystem, SES is driving impact that goes far beyond coverage. The company is headquartered
Xsolla Expands Global Payment Coverage Across 18 Markets With 6 Trusted Local Payment Methods to Help Developers Reach New Players Worldwide3.3.2026 18:00:00 CET | Press release
Amazon Pay Japan, Zain Cash, Tamara, M-Pesa, Zamtel, and the Aircash app and vouchers are now available through Xsolla Xsolla, a global video game commerce company that helps developers launch, grow, and monetize their games, today announced a major expansion of its global payments portfolio across 18 markets in Europe, the Middle East, Africa, and Asia. As developers continue to expand into high-growth and emerging markets, this expansion enables developers to reach new paying users, improve conversion rates, and deliver payment experiences tailored to local player preferences. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260303816373/en/ Graphic: Xsolla The newly supported payment methods include:Local Amazon Pay in Japan, with over 100 million registered Amazon Japan accounts, provides fully localized checkout experiences in Japanese Yen Zain Cash in Iraq is expanding access to mobile-first payment options in a rapidly
SES Announces Annual General Meeting of Shareholders3.3.2026 17:42:00 CET | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Annual General Meeting of SES, Société Anonyme, to be held at the Company’s registered office at Château de Betzdorf, L-6815 Betzdorf (the “Company”), Luxembourg, on Thursday 2 April 2026 at 10:30 a.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Presentation by the Chairman of the Board of Directors of the 2025 activities report of the Board of Directors Presentation of the main developments during 2025 and of the outlook Presentation of the audit report Approval of annual financial statements, balance sheet and profit and loss account as of 31 December 2025 Approval of consolidated financial statements as of 31 December 2025 Allocation of 2025 profits and transfers between reserve accounts Discharge of the members of the Board of Directors Determination of the number of Directors Confirmation of the co-optation of Joseph Cohen and determination o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom